Stay updated on Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The page now displays the ClinicalTrials.gov record for pembrolizumab and EDP1503 in advanced melanoma, including study details, eligibility criteria, and outcome measures. The record shows the study as terminated because the drug supply is no longer available.
    Difference
    50%
    Check dated 2026-11-08T06:47:30.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The footer now shows site revision v3.8.0 instead of v3.7.2.
    Difference
    0.2%
    Check dated 2026-11-01T06:45:16.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    A site-wide notice says NIH content may use “Super Intelligence” (SI) instead of “Artificial Intelligence” (AI) during a terminology transition. The clinical trial record itself remains inaccessible.
    Difference
    1%
    Check dated 2026-10-25T07:18:47.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    The site footer revision identifier changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-18T05:45:31.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The footer revision identifier was updated from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-11T07:57:59.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    The study page for NCT03595683 now shows a 403 Forbidden error, replacing the expected content with an access-denied message and preventing access to the study details.
    Difference
    19%
    Check dated 2026-09-20T03:17:38.000Z thumbnail image

Stay in the know with updates to Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial page.